KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Current Assets (2018 - 2025)

Historic Current Assets for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to $545.7 million.

  • Vir Biotechnology's Current Assets fell 4788.9% to $545.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $545.7 million, marking a year-over-year decrease of 4788.9%. This contributed to the annual value of $1.0 billion for FY2024, which is 3436.34% down from last year.
  • Per Vir Biotechnology's latest filing, its Current Assets stood at $545.7 million for Q3 2025, which was down 4788.9% from $735.7 million recorded in Q2 2025.
  • Over the past 5 years, Vir Biotechnology's Current Assets peaked at $2.6 billion during Q1 2022, and registered a low of $545.7 million during Q3 2025.
  • In the last 5 years, Vir Biotechnology's Current Assets had a median value of $1.2 billion in 2024 and averaged $1.5 billion.
  • Per our database at Business Quant, Vir Biotechnology's Current Assets surged by 16536.94% in 2022 and then tumbled by 4856.78% in 2024.
  • Vir Biotechnology's Current Assets (Quarter) stood at $1.6 billion in 2021, then soared by 61.19% to $2.5 billion in 2022, then plummeted by 36.95% to $1.6 billion in 2023, then tumbled by 34.36% to $1.0 billion in 2024, then tumbled by 47.65% to $545.7 million in 2025.
  • Its Current Assets was $545.7 million in Q3 2025, compared to $735.7 million in Q2 2025 and $932.2 million in Q1 2025.